Director Marco Maria Brughera filed a Form 4 with the SEC on September 16, 2026, disclosing the exercise of stock options and same-day sale of common shares in Fennec Pharmaceuticals Inc. (NASDAQ:FENC) on September 15, 2026, pursuant to a pre-established 10b5-1 plan.

Key Highlights

  • Option exercise: Brughera acquired 15,545 common shares via an "M" (exercise of in-the-money or at-the-money derivative) transaction at an exercise price of $2.11 per share.
  • Same-day sale: All 15,545 shares were sold the same day at $10.29 per share under transaction code "S."
  • Resulting ownership: Following both transactions, Brughera held 0 common shares directly, according to the filing.
  • Remaining options: The filing reports 220,000 stock options beneficially owned directly following the reported transactions, with an exercise price of $2.11 and an expiration date of December 30, 2026.
  • 10b5-1 plan: Both the exercise and sale were made pursuant to a 10b5-1 plan adopted on June 16, 2026, as noted in the filing's explanation of responses.
  • Role: Brughera is identified as a Director of Fennec Pharmaceuticals Inc.

Director Brughera's Option Exercise and Share Sale at Fennec Pharmaceuticals

According to the Form 4 filed September 16, 2026, Marco Maria Brughera, a director of Fennec Pharmaceuticals Inc. (NASDAQ:FENC), exercised stock options covering 15,545 common shares at a price of $2.11 per share on September 15, 2026. The filing identifies the underlying option as having become exercisable on December 30, 2016, with an expiration date of December 30, 2026. The exercise was conducted under transaction code "M," consistent with the exercise of a derivative security.

On the same date, the filing discloses, Brughera disposed of all 15,545 acquired shares at $10.29 per share under transaction code "S." Following both transactions, his direct beneficial ownership of common shares stood at 0, the filing states. The filing further indicates that 220,000 stock options remain directly beneficially owned following the reported transactions, retaining the same $2.11 exercise price.

The filing notes in its explanation of responses that the option exercise and the share sale were each made "pursuant to a 10b5-1 plan adopted on June 16, 2026." The filing also bears a checkbox indicating that the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Brughera's address is listed as c/o Fennec Pharmaceuticals, Inc., PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709.

What Was Disclosed

The filing reports a same-day option exercise and sale of 15,545 common shares by a Fennec Pharmaceuticals director on September 15, 2026, both carried out under a 10b5-1 plan. After the transactions, the director held no common shares directly and retained 220,000 options.